

Zhan, Jingxin

 Beijing

Capital Market

Corporate / Merger & Acquisition

Telecom, Media & Technology (TMT)



Direct: 86-10-6584-6581

Telephone: 86-10-6584-6688

Fax: 86-10-6584-6666

Email: zhanjingxin@glo.com.cn

Practice Areas

Jingxin Zhan is a partner in Beijing Office of Global Law Office. She is specialized in capital market, M&A and compliance, involving industries of TMT, manufacturing and medical, etc. She has work experience of in-house counsel of listed internet companies and securities regulatory agencies, which enables her to advise clients with profound understanding on the essence of legal issues from both of corporate and regulatory perspectives.

Jingxin Zhan has advised and participated in many overseas listing projects and has rich experience in M&A, private equity financing, outbound investment and cross-border transactions. Jingxin Zhan also worked in securities regulatory agencies and has a deep understanding of domestic and foreign securities regulatory systems. During her work in the securities regulatory agency, Jingxin Zhan researched on the IPO and M&A of new economic enterprises, especially the overseas listing, private placement of listed companies in A shares market, and disclosure of equity ownership of listed companies and had several publications.

Work Experience

Prior to joining Global Law Office in 2019, Jingxin Zhan worked in China Institute of Finance and Capital Markets and served as an in-house counsel in listed internet companies for many years. Prior to that, Jingxin Zhan was an associate of Global Law Office.

Admission

The PRC and New York State, US.

Education

2011- 2012 University of Washington, LL.M.

2003-2007 University of International Business and Economics, LL.B.

Publications

Insiders Disclosure Policy of Listed Company, From The Perspective of Baoneng's Acquisition of Vanke, Tstinghua Financial Review, Jan 2017

Pricing of Private Placement of Listed Companies, Finance Regulation Research, No.3, 2017

Languages

Chinese, English

News updates

GLO advises CARsgen Therapeutics Holdings Limited (HKEX: 02171) on its initial public offering and listing on the main board.
2021-06-18

